Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
June 04, 2019

TEL AVIV, Israel , June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:  VBLT ), announced that Dr. Dror Harats , CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the recent VB-111 progress,...

June 03, 2019

VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03) CA-125 response (GCIG) was reported in 58% of evaluable patients and was predictive of overall survival, in patients treated with a therapeutic dose of VB-111...

June 03, 2019

TEL AVIV, Israel , June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology ( ASCO ) annual meeting, showed a survival...

May 23, 2019

TEL AVIV, Israel , May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology ( ASCO ) 2019 Annual Meeting, to be held May 31 - June 4,...

May 15, 2019

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019 , and provided a corporate update. “As we continue to advance development of...

May 06, 2019

TEL AVIV, Israel , May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast...

March 28, 2019

Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM and colon cancer Signed strategic agreement for VB-201 for veterinary use; potential payments to VBL may exceed €50 million...

March 25, 2019

TEL AVIV, Israel , March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting , to be held March 29 - April 3, 2019 at...

March 19, 2019

Data Presented at Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer® TEL AVIV, Israel , March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111...

March 14, 2019

TEL AVIV, Israel , March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

View all press releases »